In this month’s episode, Senior Reporter Katie Adams discussed some of the executive moves, exits and layoffs that occurred recently in the healthcare sector. She also interviewed Claire ...

INVEST is the flagship event for MedCity News, bringing together healthcare and life science investors, startups and stakeholders in one venue to network and talk about innovations shaping the ...

Amazon’s health benefits program continues to expand. Amazon customers eligible for Teladoc Health’s services in diabetes, hypertension, pre-diabetes and weight management can now enroll ...

With mandatory Alternative Payment Model Performance Pathway (APP) Reporting beginning in Performance Year 2025, the time to act is now. Reporting quality on all beneficiaries marks a major shift ...

Last year’s M&A activity in the healthcare sector signaled an unsteady financial recovery for the nation’s hospitals, according to a new report from Kaufman Hall. The report found that there ...

or managing provider and staff workloads are informed by the metrics a physician practice tracks. A new report from Relatient offers a checklist designed to help healthcare organizations optimize ...

Imagine a patient with breast cancer, who’s been prescribed a standard chemotherapy treatment. The patient completes the treatment only to find out the cancer is still spreading. Upon further ...

A blockbuster AstraZeneca drug may now be used as an earlier treatment for mantle cell lymphoma (MCL), making it the first in its class approved as a first-line therapy for this rare and ...

On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...

When Galapagos and Gilead Sciences entered a global drug R&D collaboration six years ago, the deal focused on Galapagos’s capabilities as a developer of small molecule drugs. Fast forward to ...

Roughly 80% of women will get human papillomavirus (HPV) in their lifetime. For many, especially those who have gotten an HPV vaccine, the virus will go away on its own within two years.

Pfizer Chairman and CEO Albert Bourla did not mince his words at the 43rd annual J.P. Morgan Healthcare Conference in San Francisco on Monday regarding the controversial positions that Robert F.